What to Expect at the 8th T-Cell Engager Therapeutics Summit?
With the rapid acceleration of T cell engager innovation and the broadening of immunotherapy applications, much of today’s clinical progress remains centered around familiar CD3 based formats and a small number of validated tumor associated antigens. In solid tumors especially, early generation TCE programs continue to cluster around targets such as DLL3, HER2, CLDN6, and PSMA, while autoimmune development is still dominated by mechanisms that deplete pathogenic B or T cell subsets.
As questions grow around how many similar TCEs directed at crowded targets or relying on well-trodden CD3 geometries can meaningfully differentiate in the clinic, the field is increasingly calling for a new wave of innovation that meaningfully addresses durability, toxicity, tumor penetration, co-stimulation, and disease-specific biology.
As the industry’s longest-standing and definitive forum dedicated to immune cell redirecting therapeutics, the 8th T-Cell Engager Therapeutics Summit is committed to spotlighting the next frontier of TCE science, showcasing the breakthrough engineering strategies, translational insights, and mechanistic advances that will shape the next generation of safer, more potent, and more precisely targeted T cell engagers.
Unmissable Event Highlights for 2026
Engineer the next wave of co-stimulatory & conditionally activated T-Cell Engagers
Gain exclusive, actionable strategies from Rondo Therapeutics and Myrio Therapeutics as they reveal cutting-edge approaches to designing co-stimulatory and tumor microenvironment-activated TCEs that dramatically enhance specificity and safety.
Strengthening Clinical Success with Insights from Leading Developers
Learn directly from AstraZeneca, and Twyce Therapeutics as they share real clinical experience to help you overcome resistance, minimize toxicity, and improve the translational success of your advancing TCE programs.
Accelerate IND Readiness with Step-Up Dosing, PK/PD & Safety Frameworks
With guidance from Jazz Pharmaceuticals, QLSF Biotherapeutics, Regeneron, and Zymeworks, you’ll gain proven strategies to optimize dosing, strengthen safety packages, and streamline regulatory preparation for a faster path to IND approval.
Build Next Generation, Multi Lineage & Multi Specific Engagers
Explore advanced engineering platforms from EvolveImmune, Xencor, and Stereo Bio to discover how multi specificity, multi lineage engagement, and CD2 co stimulation are unlocking more durable, potent and broadly effective TCE designs.
What’s New?
Two Brand New Parallel Conference Tracks
This year introduces two dedicated content streams: Discovery & Engineering and Preclinical to Clinical Translation, allowing you to customize your experience and dive deeper into the challenges that matter most to your role, your modality, and your pipeline stage.
Fresh Clinical Insights into Combination Strategies & Precision Immunotherapy
As combination approaches reshape the immuno oncology landscape, hear from Amgen and Regeneron as they reveal the latest clinical evidence on chemo immunotherapy integration, co stimulation pairings, and combination ready TCE design to unlock deeper, more durable responses in solid tumors.
Divide & Conquer
Discovery, Design & Engineering
Hear from:
and more on topics including:
- Enhancing Immune Persistence by Integrating Site-Specific Co-stimulation to Achieve Durable and Targeted Anti-Tumor Responses
- Harnessing Avidity-Based Binding Logic to Improve T-cell Engager Selectivity for Solid Tumors
- Advancing Masking Technology & Binder Selection to Improve Selective Activation and Maximize Tumor-Specific Engagement
- Utilizing Advanced Platforms to Engineer the Next Generation of Curative T-Cell Engagers
Preclinical & Translational
Hear from:
on topics including:
- Overcoming Therapeutic Resistance by Engineering Adaptive Immune Engagers to Transform Tumor Outcomes
- Accelerating Clinical Readiness by Implementing Advanced Predictive Modelling to Navigate an Evolving Regulatory Environment
- Leveraging Mechanistic Biomarkers to Refine Clinical Dosing Strategies and Ensure Patient Safety During TCE Administration
- Navigating Early Clinical Development of TCE Combination Therapies for Long Term Success
Explore the Full Event Guide
- 120+ Industry Attendees
- 28+ World-Class Speakers
- 8+ Hours of Unrivalled Networking Opportunities
- 6 Deep-Dive Workshops
- 1 Modality at the Front & Center
- The Only Industry Forum Dedicated to Advancing T-Cell Engagers to Transform the Oncology and Autoimmune Landscapes
Attending Companies Include
Explore the Brand-New Agenda
Hear the latest industry breakthroughs in T-Cell Engager development and gain exclusive modality and platform insights during our packed agenda.
Partner With Us
Position yourself as the go-to service provider of the rapidly progressing T-Cell Engager landscape to ensure your brand is at the heart of deals in this evolving space.
Join Biopharma Experts
Be part of the most critical conversations shaping the future of solid tumor and autoimmune therapy, where you can connect with like-minded experts across every stage of drug development.